Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy
The primary aim of the study is to identify genomic markers (circulating tumor cells (CTCs),
 circulating tumor DNA (ctDNA), transcriptomic markers) as biomarkers of response to
 neoadjuvant chemotherapy (NAC) among patients with invasive breast cancer.
The study aims to evaluate genetic markers (i.e. CTCs and ctDNA) in breast tumors to predict
 therapy response and metastatic risk. We aim to investigate genomic markers of treatment
 response and outcomes in breast cancer patients treated with neoadjuvant chemotherapy. The
 role of CTCs and ctDNA in predicting response to NAC will also be investigated.
Inclusion Criteria:

 1. Subjects must give appropriate written informed consent prior to participation in the
 study.

 2. Subjects must be women or men age 18+.

 3. Subjects must be receiving neoadjuvant chemotherapy for breast cancer. All
 chemotherapy types and regimens are acceptable (systemic therapy will determined by
 the overseeing medical oncologist).

 4. Biopsy-confirmed diagnosis of invasive breast cancer (i.e. ER+/-, PR+/-, HER2+/-).

 5. Stage I-III disease according to the AJCC v7 criteria.

 Exclusion Criteria:

 1. Subjects with a past medical history of abnormalities, significant injury, or medical
 or surgical procedures (e.g. silicone/saline implants) involving either breast,
 exclusive of the lesion at issue.

 2. Subjects, who, in the opinion of the investigator or clinical research coordinator,
 may not otherwise be appropriate for inclusion into the study, such as significant
 anxiety.